UPDATE: Northland Capital Markets Starts Opiant Pharma (OPNT) at Outperform

(updated to correct current rating)

Northland Capital Markets analyst Carl Byrnes initiates coverage on Opiant Pharma (NASDAQ: OPNT) with a Outperform rating and a price target of $42.00.

The analyst comments "Opiant is a leading developer of therapeutics for drug overdose and addictive disorders. The Co. has an established track record, developing NARCAN® for opioid overdose from inception to approval in 3 years. The current valuation, in our view, woefully understates Opiant's extensive pipeline, its royalty stream from NARCAN® sales, government-based funding of key programs, and cash."

For an analyst ratings summary and ratings history on Opiant Pharma click here. For more ratings news on Opiant Pharma click here.

Shares of Opiant Pharma closed at $10.25 yesterday.

You May Also Be Interested In

• Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
• Legence Corp (LGN) PT Lowered to $100 at BTIG
• Tencent Holdings (700:HK) (TCEHY) PT Lowered to HK$625 at Benchmark to Reflect Downward Earnings Revisions